Sinotherapeutics Inc.'s product Dapagliflozin Metformin Sustained-Release Tablets has obtained the drug registration certificate.

Sinotherapeutics Inc. (688247.SH) announced that recently, the company received a notification from the National Medical Products Administration that its metformin sustained-release tablets containing dapagliflozin have been officially approved. This makes it the first domestically approved generic drug of its kind in China. The metformin sustained-release tablets containing dapagliflozin approved by the company are the first domestically approved generic drug of its kind in China, used for the treatment of type 2 diabetes. The original drug was developed by AstraZeneca and was approved for market in China in June 2023, and has been included in the national medical insurance category B for reimbursement.